CYP11B2 and hyperaldosteronism: However, there may be mutations in different driving genes in different nodules of the same APA [4,5] and mutations were also found in the adrenal glands of patients without APA or with secondary nodules expressing CYP11B2, indicating that these mutations may not be initiating factors for PA, but rather compensatory responses to hyperaldosteronism [6,7].